Navigation Links
Genmab Initiates Zalutumumab Combination Study in Colorectal Cancer

Summary: Genmab has Initiated a Phase I/II Study of Zalutumumab in Combination With Irinotecan Chemotherapy to Treat Refractory Colorectal

Cancer Patients

COPENHAGEN, Denmark, May 30 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today it has initiated a Phase I/II study of zalutumumab (HuMax-EGFr(TM)) in combination with irinotecan chemotherapy to treat colorectal cancer (CRC). The study will include a maximum of 97 patients who have failed standard chemotherapy and progressed during or within three months of stopping cetuximab-based therapy.

"We are glad to expand the zalutumumab program with this new indication," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab.

About the trial This open label study consists of two parts. In both parts of the study, patients will receive weekly doses until disease progression. Part 1 will include 3 to 15 patients who will receive weekly doses of first 8mg/kg of zalutumumab in combination with bi-weekly irinotecan and if safe patients will subsequently receive 16 mg/kg zalutumumab in combination with irinotecan.

Part 2 will be an open label randomized parallel group enrolling 14 to 82 patients pending the number of treatment arms and early termination from part 1. Patients in part 2 will receive weekly doses of zalutumumab with or without bi-weekly irinotecan administration until disease progression. In total a maximum of 97 patients will be enrolled into the study.

Safety data from Part 1 of the trial will be evaluated by an independent data monitoring committee who will determine if it is safe to begin Part 2. The objective of the study is to evaluate the safety and efficacy of zalutumumab in combination with irinotecan. The primary endpoint of the study is adverse events.

About Colorectal Cancer

CRC is a public health problem in developed countries. Although potentially curable in early stages, a proportion of patients will present with or eventually develop metastatic, incurable disease.

About Genmab A/S

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for unmet medical needs. Using cutting-edge antibody technology, Genmab's world class discovery, development and manufacturing teams have created and developed an extensive pipeline of products for potential treatment of a variety of diseases including cancer and autoimmune disorders. As Genmab advances towards a commercial future, we remain committed to our primary goal of improving the lives of patients who are in urgent need of new treatment options. For more information on Genmab's products and technology, visit

This press release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Genmab is not under an obligation to up-date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law.

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R); HuMax-EGFr(TM); HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM); HuMax-CD32b(TM) and UniBody(R) are all trademarks of Genmab A/S.


Helle Husted

Sr. Director

Investor Relations

T: +45-33-44-77-30

M: +45-25-27-47-13


Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Genmab Announces 2007 First Half Year Results
2. Genmab Announces Encouraging Preclinical Data for ofatumumab
3. Genmab Discloses Target and Development Plans for HuMax-Inflam
4. Genmab Announces Asset Exchange Agreement
5. Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study
6. Genmab A/S - Company Announcement
7. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
8. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
9. Genmab Announces Results for the First Nine Months of 2007
10. Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study
11. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
Post Your Comments:
(Date:11/24/2015)... - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" ... , President and Chief Executive Officer of ProMetic, will be ... th Annual Healthcare Conference to be held at the ... st , at 8.50am (ET) and ProMetic,s management team ... presentation will be available live via a webcast accessible at ...
(Date:11/24/2015)... 2015 HemoShear Therapeutics, LLC, a privately ... metabolic disorders, announced today the appointment of ... Directors (BOD). Mr. Watkins is the former president ... (HGS), and also served as the chairman of ... , Chairman and CEO of HemoShear Therapeutics. "The ...
(Date:11/24/2015)... NEW YORK , November 24, 2015 /PRNewswire/ ... Bristol-Myers Squibb in a European ... Company in which the companies will work closely together ... other areas of unmet medical need. The collaboration is underpinned ... the latest LSP fund. This is the first investment by ...
(Date:11/24/2015)... According to two new studies, fewer men are ... that many doctors, scientists, and public health experts have been ... PSA tests being done, will there be more men dying ... Samadi, "Despite the efforts made in regards to early ... cancer cause of death in men, killing approximately 27,500 men ...
Breaking Biology Technology:
(Date:10/29/2015)... , Oct. 29, 2015 Today, ... a partnership with 2XU, a global leader in ... a smart hat with advanced bio-sensing technology. The ... athletes to monitor key biometrics to improve overall ... partnership, the two companies will bring together the most ...
(Date:10/26/2015)... 26, 2015 ... adds Biometrics Market Shares, Strategies ... well as Emerging Biometrics Technologies: Global ... its collection of IT and Telecommunications ... --> . ...
(Date:10/23/2015)... GOLETA, California , October 23, 2015 /PRNewswire/ ... SensoMotoric Instruments (SMI) announce a mobile plug and play ... during interactive real-world tasks SensoMotoric Instruments (SMI) ... their established wearable solutions for eye tracking and physiological ... captured with SMI Eye Tracking Glasses 2w ...
Breaking Biology News(10 mins):